BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 12062596)

  • 41. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
    Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
    J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer.
    Keene KS; Harman EM; Knauf DG; McCarley D; Zlotecki RA
    Am J Clin Oncol; 2005 Jun; 28(3):217-22. PubMed ID: 15923791
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
    Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
    Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
    Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.
    Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
    J Clin Oncol; 1996 Apr; 14(4):1065-70. PubMed ID: 8648358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer.
    Kobayashi M; Matsui K; Hirashima T; Nitta T; Sasada S; Tada T; Minakuchi K; Furukawa M; Ogata Y; Kawase I
    Int J Clin Oncol; 2006 Aug; 11(4):314-9. PubMed ID: 16937306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small-cell lung cancer--impact of total treatment time.
    Nyman J; Bergman B; Mercke C
    Acta Oncol; 1998; 37(6):539-45. PubMed ID: 9860311
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.
    Takeda K; Negoro S; Tanaka M; Fukuda H; Nakagawa K; Kawahara M; Semba H; Kudoh S; Sawa T; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2011 Jan; 41(1):25-31. PubMed ID: 20802006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial.
    Robert F; Spencer SA; Childs HA; Zhang R; Meredith RF; Wheeler RH; Hawkins MH; Carey D
    Lung Cancer; 2002 Aug; 37(2):189-99. PubMed ID: 12140142
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
    Jain AK; Hughes RS; Sandler AB; Dowlati A; Schwartzberg LS; Dobbs T; Schlabach L; Wu J; Muldowney NJ; Choy H
    J Thorac Oncol; 2009 Jun; 4(6):722-7. PubMed ID: 19404213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non-small cell lung cancer.
    Jeremic B; Jevremovic S; Mijatovic L; Milisavljevic S
    Cancer; 1993 Jun; 71(11):3732-6. PubMed ID: 8387885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer.
    Liao Z; Komaki R; Stevens C; Kelly J; Fossella F; Lee JS; Allen P; Cox JD
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):558-65. PubMed ID: 12062597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1.
    Robinet G; Thomas P; Breton JL; Léna H; Gouva S; Dabouis G; Bennouna J; Souquet PJ; Balmes P; Thiberville L; Fournel P; Quoix E; Riou R; Rebattu P; Pérol M; Paillotin D; Mornex F
    Ann Oncol; 2001 Jan; 12(1):59-67. PubMed ID: 11249050
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer.
    Ajlouni M; Chapman R; Kim JH
    Cancer J Sci Am; 1996; 2(6):314-20. PubMed ID: 9166551
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage III non-small-cell lung cancer.
    Shibamoto Y; Jeremic B; Acimovic L; Milicic B; Nikolic N
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):295-300. PubMed ID: 11380214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report.
    Lee JS; Komaki R; Fossella FV; Glisson BS; Hong WK; Cox JD
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):479-86. PubMed ID: 9806504
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
    Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
    J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.